

SUPPLEMENTARY MATERIAL TO
**Pharmaceuticals in Belgrade's wastewater: impact on surface waters
and environmental risk assessment**

LJILJANA M. TOLIĆ STOJADINOVIĆ^{1*}, SVETLANA D. GRUJIĆ², NIKOLINA N.
ANTIĆ³, AND TATJANA M. ĐURKIĆ²

¹Innovation Center of the Faculty of Technology and Metallurgy, Karnegijeva 4, 11000
Belgrade, Serbia; ²University of Belgrade, Faculty of Technology and Metallurgy, Karnegijeva
4, 11000 Belgrade, Serbia; and ³Customs laboratory, Customs Administration of the Republic of
Serbia, Bulevar Zorana Đinđića 155a, 11000 Belgrade, Serbia.




Fig. S-I. Mobile phase gradient profile.

* Corresponding author. E-mail: ljtolic@tmf.bg.ac.rs

Table S-I. MS operating parameters for selected pharmaceuticals.

Pharmaceuticals	Precursor ion (<i>m/z</i>)	Quantification reaction	Collision energy (%)	Confirmation reaction	Collision energy (%)
Trimethoprim	291 [M+H] ⁺	291→230	44	291→123	44
Metoprolol	268 [M+H] ⁺	268→191	37	268→218	37
Sulfamethoxazole	254 [M+H] ⁺	254→188	34	254→156	34
Azithromycin	749 [M+H] ⁺	749→591	30	591→434	28
Bisoprolol	326 [M+H] ⁺	326→116	31	326→222	31
Enalapril	377 [M+H] ⁺	377→234	30	377→303	30
Cilazapril	418 [M+H] ⁺	418→211	25	211→183	32
Erythromycin	734 [M+H] ⁺	734→576	26	734→716	26
Bromazepam	316 [M+H] ⁺	316→288	36	288→261	35
Amlodipine	409 [M+H] ⁺	409→238	25	409→294	25
Carbamazepine	237 [M+H] ⁺	237→194	34	237→220	34
Lorazepam	321 [M+H] ⁺	321→303	32	303→275	26
Diazepam	285 [M+H] ⁺	285→257	40	257→228	39
Atorvastatin	559 [M+H] ⁺	559→466	25	559→440	25
Diclofenac	296 [M+H] ⁺	296→278	28	278→250	22
Clopidogrel	322 [M+H] ⁺	322→212	28	212→184	23
Simvastatin	419 [M+H] ⁺	419→285	21	419→199	21

Table S-II. The sampling site description.

Sample	Latitude	Longitude	Site description
<i>Surface water (SW)</i>			
SW1	44.7962	20.4259	The Sava; 4 km before the confluence
SW2	44.7989	20.4336	The Sava; 3.5 km before the confluence; downstream from the largest WW canal (WW1)
SW3	44.8019	20.4400	The Sava; 2.7 km before the confluence
SW4	44.8233	20.4368	The Danube; 500 m before the confluence
SW5	44.8241	20.4434	The confluence
SW6	44.8305	20.4828	The Danube; 3.6 km after the confluence
SW7	44.8279	20.5091	The Danube; 5.6 km after the confluence
SW8	44.8231	20.5359	The Danube; 8.5 km after the confluence; small bay
<i>Wastewater (WW)</i>			Number of inhabitants connected to WW canal
WW1	44.7976	20.4346	The largest WW canal; catchment area of 7,277 ha 500,000
WW2	44.8118	20.4494	Catchment area of 113 ha 23,000
WW3	44.8229	20.4419	The second large WW canal; catchment area of 2,620 ha 225,000
WW4	44.8293	20.4694	Catchment area of 92 ha 17,000
			Catchment area of 1,112 ha 165,000
WW6	44.8239	20.5035	Catchment area of 50 ha 5,000
WW7	44.8277	20.5430	Catchment area of 116 ha 7,000

Table S-III. Lowest PNEC values of detected pharmaceuticals in freshwater obtained from NORMAN database.

Pharmaceuticals	Norman PNEC ID	CAS No.	Taxon. group	Scientific name	Applied AF	Justification	Derivation method	Lowest PNEC freshwater ($\mu\text{g L}^{-1}$)	Ref
Trimethoprim	PNEC-ID-0348354	738-70-5	n.r. ^a	n.r.	0	n.r.	n.r.	0.5	1
Metoprolol	PNEC-ID-0348060	51384-51-1	PI	<i>Desmodesmus subspicatus</i>	50	n.r.	deterministic	8.6	2
Sulfamethoxazole	PNEC-ID-0348126	723-46-6	P	<i>Synechococcus leopoliensis</i>	10	n.r.	deterministic	0.6	2
Azithromycin	PNEC-ID-0347903	83905-01-5	PI	<i>Microcystis aeruginosa</i>	10	n.r.	deterministic	0.019	2
Bisoprolol	PNEC-ID-0348209	66722-44-9	PIV	n.r.	50	n.r.	deterministic	92	3
Enalapril	PNEC-ID-0031812	75847-73-3	fish	-	1000	^b	deterministic	1.58	4
Carbamazepine	PNEC-ID-0347929	298-46-4	I	<i>Daphnia pulex</i>	50	n.r.	deterministic	2	2
Diazepam	PNEC-ID-0257661	439-14-5	F	<i>Danio rerio</i>	10	^c	deterministic	0.29	5
Atorvastatin	PNEC-ID-0348226	134523-00-5	PIV	n.r.	10	n.r.	deterministic	8.5	6
Diclofenac	PNEC-ID-0348270	15307-86-5	n.r.	n.r.	0	n.r.	n.r.	0.04	7

^a n.r. – not reported^b One predicted short-term L(E)C50 from each of three trophic levels (i.e., base set)^c Long-term results (e.g., EC10 or NOECs) from at least three species (normally fish, Daphnia and algae) representing three trophic levels

Table S-IV. Validation parameters of the analytical method: recoveries and relative standard deviations (RSD), limits of detection (LOD) and quantification (LOQ), and linearity correlation coefficient (R^2).

Pharmaceuticals	Recovery, % (RSD, %)		LOD, ng L ⁻¹	LOQ, ng L ⁻¹	R ²
	Spiking level, ng L ⁻¹				
	100	1000			
Trimethoprim	88 (8)	92 (5)	11.0	36.8	0.993
Metoprolol	87 (12)	87 (5)	3.3	11.1	0.993
Sulfamethoxazole	83 (5)	70 (8)	30.0	100.0	0.999
Azithromycin	58 (7)	55 (11)	5.2	17.4	0.999
Bisoprolol	71 (12)	84 (11)	5.2	17.2	0.997
Enalapril	117 (19)	110 (11)	30.0	100.0	0.993
Cilazapril	88 (2)	101 (7)	3.9	13.2	0.997
Erythromycin	56 (17)	62 (10)	4.1	13.7	0.997
Bromazepam	89 (11)	93 (7)	25.0	83.3	0.998
Amlodipine	81 (4)	96 (2)	23.4	77.9	0.998
Carbamazepine	107 (8)	101 (8)	3.6	11.8	0.999
Lorazepam	83 (13)	93 (6)	14.3	47.6	0.996
Diazepam	86 (10)	95 (4)	21.1	70.3	0.990
Atorvastatin	95 (2)	83 (5)	19.6	65.5	0.999
Diclofenac	83 (20)	92 (13)	23.1	76.9	0.993
Clopidogrel	87 (7)	94 (1)	9.3	30.9	0.999
Simvastatin	118 (19)	107 (7)	50.0	166.7	0.998

Table S-V. Hazard identification of detected pharmaceuticals.

Pharmaceutical	Persistence	Bioaccumulation	Toxicity	Mobility	Endocrine Disruption (ED)	Ref.
Trimethoprim	Moderate	Low	Moderate	High	Not reported	8
Enalapril	Moderate	Low	Low	Moderate	Not classified as ED	16,17
Cilazapril	Moderate	Low	Low	Moderate	Not reported	18,19
Erythromycin	High	Low	High	High	Potential disruptor	20
Carbamazepine	High	Low	High	High	Potential to function as an ED	21-23
Lorazepam	Moderate	Low	Moderate	Moderate	Functional ED uncertainty	24-26
Diazepam	Moderate-high	Low-moderate	Moderate	Moderate	Potential to interact with endocrine function	27
Atorvastatin	Low-moderate	Low	Moderate	Moderate	Not reported	28,29
Diclofenac	Moderate-high	Low	Moderate-high	Moderate-high	Possible ED	30,31
						32,33

REFERENCES

1. J. Bengtsson-Palme, D.G. J. Larsson, *Environ. Int.* **86** (2016) 140 (<https://doi.org/10.1016/j.envint.2015.10.015>)
2. Proposals for Quality Criteria for Surface Waters, Oekotexzentrum centre ecotex, Available at: <https://www.oekotoxzentrum.ch/expertenservice/qualitaetskriterien/qualitaetskriterien-vorschlaege-oekotoxzentrum/> (date accessed: April 24, 2025)
3. M. Baumann, K. Weiß, I. Kirst, W. Kopf, *Umweltqualitätsnormen (UQN) für Binnengewässer*, Umweltbundesamt, Dessau-Roßlau, Germany, 2020, p. 45 (<https://doi.org/10.60810/openumwelt-5724>)
4. R. Aalizadeh, P. von der Ohe, N.S. Thomaidis, *Environ. Sci.: Process. Impacts* **19** (2017) 438 (<https://www.norman-network.com/nds/susdat/>)
5. US-EPA (2018) AQUIRE database, Available at: <https://cfpub.epa.gov/ecotox/search.cfm> (date accessed: May 9, 2025)
6. ad hoc EQS List, Oekotexzentrum centre ecotex, 2022, Available at: <http://www.ecotoxcentre.ch/expert-service/quality-criteria/quality-criteria-for-surface-waters> (date accessed: May 9, 2025)
7. European Commission, ANNEXES to the Proposal for a Directive of the European Parliament and of the Council amending Directive 2000/60/EC establishing a framework for Community action in the field of water policy, Directive 2006/118/EC on the protection of groundwater against pollution and deterioration and Directive 2008/105/EC on environmental quality standards in the field of water policy, 2022, Available at: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://eur-lex.europa.eu/resource.html?uri=cellar:d0c11ba6-55f8-11ed-92ed-01aa75ed71a1.0001.02/DOC_2&format=PDF (date accessed: May 9, 2025)
8. J. O. Straub, *Antibiotics* **2** (2013) 115–162 (<http://dx.doi.org/10.3390/antibiotics2010115>)
9. F. Grönera, C. Höhnea, W. Kleinera, W. Kloas, *Ecotoxicol. Environ. Saf.* **141** (2017) 271 (<http://dx.doi.org/10.1016/j.ecoenv.2017.03.032>)

10. D. Love, M. Slovisky, K. A. Costa, D. Megarani, Q. Mehdi, V. Colombo, E. Ivantsova, K. Subramaniam, J. A. Bowden, J. H. Bisesi Jr., C. J. Martyniuk, *Environ. Toxicol. Chem.* **43** (2024) 2530 (<http://dx.doi.org/10.1002/etc.5981>)
11. A. Massarsky, V. L. Trudeau, T. W. Moon, *J. Exp. Zool.* **315** (2011) 251 (<https://doi.org/10.1002/jez.672>)
12. W. Duan, H. Cui, X. Jia, X. Huang, *Sci. Total Environ.* **820** (2022) 153178 (<http://dx.doi.org/10.1016/j.scitotenv.2022.153178>)
13. D. Archundia, C. Duwig, L. Spadini, M.C. Morel, B. Prado, M. P. Perez, V. Orsaga, J. M. F. Martins, *Environ. Int.* **130** (2019) 104905 (<https://doi.org/10.1016/j.envint.2019.104905>)
14. K. Yu, Y. Qui, Y. Shi, X. Yu, T. Dong, Y. Wu, H. Li, L. Huang, *Ecotox. Environ. Safety* **247** (2022) 114234 (<https://doi.org/10.1016/j.ecoenv.2022.114234>)
15. E. Kalugendo, P. Singh, R. Agaewal, *Sust. Chem. One World* **7** (2025) 100106 (<https://doi.org/10.1016/j.scowo.2025.100106>)
16. A. A. Godoy, I. Domingues, L. B. de Carvalho, A. C. Oliveira, C. C. de Jesus Azevedo, J. M. Taparo, P. K. Assano, V. Mori, V. de Almeida Vergara Higoalga, A. J. A. Nogueira, F. Kummroe, *Environ. Sci. Pollut. Res.* **27** (2020) 5469 (<https://doi.org/10.1007/s11356-019-07322-0>)
17. Janusinfo Bisoprolol, Available at: <https://janusinfo.se/beslutsstod/lakemedelochmiljo/pharmaceuticsandenvironment/databaseenven/bisoprolol.5.30a7505616a041a09b06299f.html> (data accessed: November 7, 2025)
18. M. Filice, A. Caferro, D. Amelio, F. Impellitteri, M. A. Iovine, M. Porretti, C. Faggio, A. Gattuso, M. C. Cerra, S. Imbrogno, *Aquat. Toxicol.* **273** (2024) 107014 (<https://doi.org/10.1016/j.aquatox.2024.107014>)
19. Janusinfo Enalapril, Available at: <https://janusinfo.se/beslutsstod/lakemedelochmiljo/pharmaceuticsandenvironment/databaseenven/enalapril.5.30a7505616a041a09b062a0e.html> (date accessed: November 6, 2025)
20. A. Kravos, A. A. Žgajnar Gotvajn, H. Prosen, *Processes* **12** (2024) 2177 (<https://doi.org/10.3390/pr12102177>)
21. Janusinfo Erythromycin, Available at: <https://janusinfo.se/beslutsstod/lakemedelochmiljo/pharmaceuticsandenvironment/databaseenven/erythromycin.5.30a7505616a041a09b063251.html> (data accessed: November 17, 2025)
22. K. Wang, T. Larkin, N. Singhal, Y. Song, *Sci. Tot. Environ.* **624** (2018) 1263 (<https://doi.org/10.1016/j.scitotenv.2017.12.243>)
23. J. Ren, S. Ni, Y. Shen, D. Niu, R. Sun, C. Wang, L. Deng, Q. Zhang, Y. Tang, X. Jiang, Z. Li, C. Li, *J. Clean. Prod.* **379** (2022) 134758 (<https://doi.org/10.1016/j.jclepro.2022.134758>)
24. Janusinfo Carbamazepine, Available at: <https://janusinfo.se/beslutsstod/lakemedelochmiljo/pharmaceuticsandenvironment/databaseenven/carbamazepine.5.30a7505616a041a09b063c57.html> (available at: November 20, 2025)
25. T. J. Scheytt, P. Mersmann, T. Heberer, *J. Contam. Hydrol.* **83** (2006) 53 (<https://doi.org/10.1016/j.jconhyd.2005.11.002>)
26. H. Chen, X. Gu, Q. Zeng, Z. Mao, *Int. J. Environ. Res. Public Health* **16** (2019) 209 (<https://doi.org/10.3390/ijerph16020209>)

27. S. A. Hernández Martínez, E. M. Melchor-Martínez, R. B. González-González, J. E. Sosa-Hernández, R. G. Araújo, J. A. Rodríguez-Hernández, D. Barceló, R. Parra-Saldivar, H. M.N. Iqbal, *Environ. Res.* **229** (2023) 115892 (<https://doi.org/10.1016/j.envres.2023.115892>)
28. K. Tolić Čop, M. Gotovuša, D. Mutavdžić Pavlović, D. Dabić, I. Grčić, *Nanomaterials* **15** (2025) 827 (<https://doi.org/10.3390/nano15110827>)
29. C. L. Overturf, M. D. Overturf, D. B. Huggett, *Comp. Biochem. Physiol. C* **183–184** (2016) 46 (<http://dx.doi.org/10.1016/j.cbpc.2016.02.001>)
30. Janusinfo Atorvastatin, Available at: <https://janusinfo.se/beslutsstod/lakemedelochmiljo/pharmaceuticalsandenvironment/databaseenven/atorvastatin.5.30a7505616a041a09b062c27.html#query/Diazepam> (data accessed: November 19, 2025)
31. M. M. Santos, R. Ruivo, M Lopez-Marques, T. Torres, C. B. de los Santos, L. F. C. Castro, T. Neuparth, *Aquat. Toxicol.* **174** (2016) 1 (<http://dx.doi.org/10.1016/j.aquatox.2016.02.001>)
32. L. Lonappan, S. Kaur Brar, R. Kumar Das, M. Verma, R. Y. Surampalli, *Environ. Int.* **96** (2016) 127 (<https://doi.org/10.1016/j.envint.2016.09.014>)
33. N. J. Efosa, W. Kleiner, W. Kloas, F. Hoffmann, *Chemosphere* **173** (2017) 69 (<http://dx.doi.org/10.1016/j.chemosphere.2017.01.030>)